DEFA14A: OraSure Confirms Altai Capital Director Nominations

OraSure Technologies confirmed receipt of director nominations from Altai Capital for its 2026 Annual Meeting, with the Board planning to review and make recommendations.

Summary

• OraSure Technologies confirmed that Altai Capital has nominated two candidates, including its founder Rishi Bajaj, for election to the Company's Board of Directors at the 2026 Annual Meeting of Stockholders.
• The Board previously interviewed Mr. Bajaj for potential service but decided to appoint an alternative candidate.
• Altai Capital has not accepted the Board's offers to engage further since that time.
• OraSure emphasized its strong, independent, and engaged Board, noting significant refreshment since 2022, with seven directors departing and three new highly qualified independent directors added.
• Steven K. Boyd, an accomplished healthcare investor, was added as an independent director in October 2025.
• John P. Kenny, a director since September 2024, was appointed Board Chair in October 2025.
• The Nominating and Corporate Governance Committee and the Board will review Altai's nominations and present recommendations in the definitive proxy statement for the 2026 Annual Meeting.
• OraSure shareholders are not required to take any action at this time.

Sentiment

Score: 5

Explanation: The filing is neutral in tone, confirming a procedural event (receipt of nominations) and outlining the company's governance process. While the nominations themselves could be seen as a negative (activist involvement), the company's response emphasizes proactive board refreshment, balancing the sentiment.

Positives

• OraSure's Board has undergone significant refreshment since 2022, with seven directors departing and three new highly qualified independent directors added.
• The addition of accomplished healthcare investor Steven K. Boyd as an independent director in October 2025.
• John P. Kenny, a director since September 2024, was appointed Board Chair in October 2025, strengthening board leadership.
• The company maintains that its Board is strong, independent, and engaged, with a focus on driving growth and value creation.

Negatives

• Receipt of director nominations from activist investor Altai Capital indicates potential shareholder dissatisfaction or a looming proxy contest.
• Altai Capital has not accepted the Board's offers for further engagement, suggesting a breakdown in communication or an unwillingness to compromise.

Risks

• Forward-looking statements are not guarantees of future performance or results, and actual outcomes may differ materially due to various important factors, including those detailed in SEC filings.
• The potential for a contested election or proxy contest with Altai Capital could divert management's attention and company resources.

Future Outlook

The Board will review Altai Capital's nominations and present its recommendations in the Company's definitive proxy statement, which will be filed with the SEC and mailed to stockholders eligible to vote at the 2026 Annual Meeting of Stockholders. The company undertakes no duty to update forward-looking statements.

Management Comments

• "OraSure maintains a strong, independent, and engaged Board."
• "We continually assess our Board composition, and as a result our Board has undergone significant refreshment, bringing in industry perspectives and executive-level experience to provide oversight as management drives growth and value creation."

Industry Context

This announcement reflects a common scenario in public markets where activist investors seek to influence corporate governance and strategy. OraSure's emphasis on proactive board refreshment and the addition of independent directors is a typical response to such challenges, aiming to demonstrate strong oversight and strategic alignment with shareholder interests, a trend observed across various industries facing activist pressure.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will need to consider the Board's recommendations regarding Altai Capital's nominees and vote at the 2026 Annual Meeting, potentially facing a contested election.
• Management: May face increased scrutiny and pressure from activist investors, requiring focus on defending current strategy and governance.
• Board of Directors: Engaged in reviewing nominations and defending its current composition and strategic direction.

Next Steps

• The Nominating and Corporate Governance Committee and OraSure's Board will review Altai's nominations.
• The Board will present its recommendation in the Company's definitive proxy statement.
• OraSure will file a definitive proxy statement with the SEC for the 2026 Annual Meeting of Stockholders.
• The definitive proxy statement will be mailed to stockholders eligible to vote at the 2026 Annual Meeting.
• The 2026 Annual Meeting of Stockholders will be scheduled.

Key Dates

Recommendation

The filing indicates a potential proxy contest, which introduces uncertainty regarding future strategic direction and governance. While the company highlights proactive board refreshment, the activist's nominations suggest dissatisfaction. Investors should hold and await the definitive proxy statement to understand the full scope of the activist's proposals and the Board's detailed response before making further investment decisions.

Keywords

OraSure Technologies, OSUR, Altai Capital, director nominations, proxy statement, corporate governance, Board of Directors, shareholder meeting, activist investor, diagnostic tests, sample management